|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
AquaBounty Technologies
| | | Phone: | (978) 648-6000 | Year Established: | 1991 | Ticker: | AQB | Exchange: | BTX | Main Contact: | Henry Clifford, VP, Marketing & Sales | | Other Contacts: | Christopher Martin, General Counsel Alejandro Rojas, DVM, COO David A. Frank, CFO Ronald L. Stotish, President & CEO
| | Company Description | AquaBounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture. Their objective is the application of biotechnology to ensure the availability of high quality seafood to meet global consumer demand.
The U.S. Food and Drug Administration is considering approval of AquAdvantage® Atlantic salmon eggs. These eggs include a gene from the Chinook salmon that provides the fish with the potential to grow to market size in half the time of conventional salmon. This fish would be the first food from a transgenic animal application approved by the FDA.
The Company’s AquAdvantage® Salmon product consists of Atlantic salmon eggs that contain a growth hormone gene from the Chinook salmon, which provides the fish with the potential to reach market size in half the time of conventional Atlantic salmon. Fish grown from AAS eggs are all female and sterile. In addition, the FDA requires that, were approval of AquaBounty’s NADA to be granted, the fish can only be grown in physically contained systems at approved facilities.
AquaBounty was originally incorporated in1991, under the name A/F Protein, to pursue the commercial development of antifreeze protein-based technology under license from the University of California at Berkeley. | |
|
|
|
|
|